Caribou Biosciences (CRBU) Net Income towards Common Stockholders (QoQ) (2020 - 2026)
Caribou Biosciences (CRBU) Net Income towards Common Stockholders (QoQ) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Caribou Biosciences | 152.90 Mn | 35.27 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.77% |
| Dec 31, 2025 | 10.77% |
| Sep 30, 2025 | 32.14% |
| Jun 30, 2025 | -10.94% |
| Mar 31, 2025 | -6.76% |
| Dec 31, 2024 | 47.03% |
| Sep 30, 2024 | -34.48% |
| Jun 30, 2024 | 35.23% |
| Mar 31, 2024 | -132.55% |
| Dec 31, 2023 | -25.74% |
| Sep 30, 2023 | 61.03% |
| Jun 30, 2023 | -143.99% |
| Mar 31, 2023 | -1.11% |
| Dec 31, 2022 | 39.57% |
| Sep 30, 2022 | 32.43% |
| Jun 30, 2022 | -235.55% |
| Mar 31, 2022 | -22.72% |
| Dec 31, 2021 | 11.90% |
| Sep 30, 2021 | -46.56% |
| Jun 30, 2021 | -8.75% |